Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely asso...
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johns...
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
Zealand Pharma announces closing of collaboration and license agreement with Roche
Zealand Pharma Announces Financial Results for the First Three Months of 2025
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and typ...
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Resolutions from Zealand Pharma's Annual General Meeting 2025
Zealand Pharma major shareholder announcement: Van Herk Investments B.
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational ...
Zealand Pharma convenes its Annual General Meeting 2025
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024
Zealand Pharma Announces Financial Results for the Full Year 2024
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Zealand Pharma to participate in the Jefferies London Healthcare Conference
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
Zealand Pharma announces that Boehringer receives U.
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dua...
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
Zealand Pharma major shareholder announcement: Bank of America Corporation
Zealand Pharma Announces Financial Results for the First Half of 2024
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
Zealand Pharma major shareholder announcement: Van Herk Investments
Total number of shares and voting rights in Zealand Pharma at June 28, 2024
Zealand Pharma completes registration of capital increase
Zealand Pharma announces completion of an upsized equity offering of 8.
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin a...
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening o...
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Age...
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
Zealand Pharma major shareholder announcement: Polar Capital
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agoni...
Zealand Pharma Announces Financial Results for the First Quarter of 2024
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Correction to Company announcement – No.
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024
Total number of shares and voting rights in Zealand Pharma at March 31, 2024
Zealand Pharma's Annual General Meeting 2024
New Employee Elected Directors to the Board of Zealand Pharma A/S
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
Zealand Pharma convenes its Annual General Meeting 2024
Zealand Pharma Announces Financial Results for the Full Year 2023
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver...
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
Total number of shares and voting rights in Zealand Pharma at January 31, 2024
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
Total number of shares and voting rights in Zealand Pharma at December 29, 2023
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of do...
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
Total number of shares and voting rights in Zealand Pharma at November 30, 2023
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
